Hangzhou Tigermed Consulting Co., Ltd
300347
Rang in Aktien
#3218
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides... Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
Aktienkurs
$7.44
Marktkapitalisierung
$5.49B
Veränderung (1 Tag)
-2.99%
Veränderung (1 Jahr)
-0.42%
Land
CN
Handel Hangzhou Tigermed Consulting Co., Ltd (300347)
Kategorie
Healthcare
P/S-Verhältnis für Hangzhou Tigermed Consulting Co., Ltd (300347)
P/S-Verhältnis zum October 2026 TTM: 5.03
Laut den neuesten Finanzberichten und dem Aktienkurs von Hangzhou Tigermed Consulting Co., Ltd beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 5.03. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 7.14.
P/S-Verlauf für Hangzhou Tigermed Consulting Co., Ltd von 2009 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 5.03 | -29.00% |
| 2025 | 7.08 | -0.76% |
| 2024 | 7.14 | 14.90% |
| 2023 | 6.21 | -51.43% |
| 2022 | 12.79 | -40.08% |
| 2021 | 21.35 | -47.22% |
| 2020 | 40.45 | 141.08% |
| 2019 | 16.78 | 97.10% |
| 2018 | 8.51 | -18.27% |
| 2017 | 10.42 | -3.42% |
| 2016 | 10.78 | -22.65% |
| 2015 | 13.94 | 33.19% |
| 2014 | 10.47 | -48.17% |
| 2013 | 20.20 | 102.21% |
| 2012 | 9.99 | -3.96% |
| 2011 | 10.40 | -35.60% |
| 2010 | 16.15 | -40.26% |
| 2009 | 27.03 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 10.72 | 113.29% |
US
|
|
| 41.70 | 729.59% |
US
|
|
| 4.19 | -16.63% |
AU
|
|
| 5.80 | 15.29% |
BE
|
|
| 10.44 | 107.75% |
NL
|
